The diagnosis of overactive bladder (OAB) is made on the basis of symptoms alone in the absence of urinary tract infection or other detectable disease.  The etiology of OAB is usually unclear, therefore, treatment is usually symptomatic.
It has long been accepted that conservative treatments are recommended first because they usually carry the least risk of causing harm. But there is increasing concern about the adverse effects of some pharmacological treatments used to treat OAB (eg, anticholinergic drugs), particularly with regard to cognitive function, and patients should be fully counselled regarding this potential risk [1]. In this regard, the search for new non-surgical treatments is ongoing. The bovine bladder piptide complex (Vezusten) was created specifically for the treatment of OAB symptoms.
The aim of the study was to evaluate the results of using the bovine bladder peptide complex Vesusten in the treatment of OAB.

The study involved 48 patients diagnosed with OAB. All of them received Vezusten® as therapy, 5 mg intramuscularly 3 times a week,  total of 10 doses.
The study consisted of two stages: a screening period lasting up to 14 days; a period for assessing the effectiveness of therapy (42 days from the start of therapy, including 21 days - the therapy period + further observation after the end of therapy). The Overactive bladder questionnaire OABq was used to assess the quality of life [2]. To evaluate symptoms, we used Total Urgency and Frequency Score (TUFS), Perception Of Intensity Of Urgency Scale (PPIUS), bladder diary.
Significance was defined as P value < 0.05. Statistical comparisons of data were performed with the non-parametric Mann–Whitney U test.

Three weeks after the end of treatment, a statistically significant decrease in the average score of the following criteria was noted: the severity of overactive bladder symptoms according to the TUFS scale, measurements of urgency symptoms according to the PPIUS scale, measurements of the frequency of urination during the day and night (p = 0.0000). The frequency of urination at night decreased by more than 2.7 times on average, while the percentage of patients who did not wake up at night to go to the toilet increased from 10 to 38 percent. Assessment of the quality of life using the OAB-q questionnaire revealed a statistically significant decrease in the severity of OAB symptoms and an improvement in the quality of life after the end of the treatment compared to the baseline level (Fig. 1).

The clinical efficacy of the bovine bladder peptide complex in relation to the severity of overactive bladder symptoms and the quality of life of patients has been proved. Considering that the effect of treatment with the drug was assessed 3 weeks after the end of therapy and was quite stable, it can be assumed that the action of Vezusten is pathogenetic or etiotropic.

The complex of bioactive bovine bladder peptides Vezusten is an effective treatment for OAB.

EAU Guidelines. Edn. presented at the EAU Annual Congress, Madrid 2025. ISBN 978-94-92671-29-5.
Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002 Sep;11(6):563-74.